Claims
- 1. An isolated polypeptide which comprises a sequence of amino acids corresponding to the amino acid sequence set out in SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:8 or SEQ ID NO:9 or a fragment of said polypeptide, wherein said polypeptide or fragment has the ability to stimulate at least one endothelial cell biological activity selected from the group consisting of cell proliferation, cell differentiation, cell migration, cell survival or vascular permeability.
- 2. A polypeptide which comprises a sequence of amino acids corresponding to the amino acid sequence set out in SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:8 or SEQ ID NO:9 or a fragment of said polypeptide, wherein said polypeptide or fragment has the ability to stimulate at least one endothelial cell biological activity selected from the group consisting of cell proliferation, cell differentiation, cell migration, cell survival or vascular permeability, and further wherein said polypeptide or fragment comprises the amino acid sequence Pro-Xaa-Cys-Val-Xaa-Xaa-Xaa-Arg-Cys-Xaa-Gly-Cys-Cys (SEQ ID NO:2).
- 3. A polypeptide according to claim 1, wherein said endothelial cells are selected from the group consisting of vascular endothelial cells and lymphatic endothelial cells.
- 4. A polypeptide according to claim 1, which comprises a sequence of amino acids corresponding to SEQ ID NO:3 or SEQ ID NO:5.
- 5. A polypeptide according to claim 4, which comprises a sequence of amino acids corresponding to SEQ ID NO:5.
- 6. A polypeptide according to claim 1, which has the ability to stimulate proliferation of endothelial cells.
- 7. A polypeptide according to claim 1, which has the ability to induce endothelial cell differentiation.
- 8. A polypeptide according to claim 1, which has the ability to induce vascular permeability.
- 9. A polypeptide according to claim 1, comprising amino acid residues 64 through 172 of SEQ ID NO:3 or 93 through 201 of SEQ ID NO:5.
- 10. A polypeptide according to claim 9, further comprising an affinity tag peptide sequence.
- 11. A polypeptide according to claim 1, wherein said polypeptide is a human protein.
- 12. A pharmaceutical composition comprising a polypeptide according to claim 1, and a pharmaceutically acceptable carrier or adjuvant.
- 13. A pharmaceutical composition according to claim 12, further comprising at least one substance selected from the group consisting of VEGF, VEGF-B, VEGF-C, PlGF, PDGF, FGF and heparin.
- 14. A protein dimer comprising a first polypeptide according to claim 1, and a second polypeptide.
- 15. A protein dimer according to claim 14, wherein said protein dimer is a homodimer in which the second polypeptide is identical to the first polypeptide.
- 16. A protein dimer according to claim 14, wherein said protein dimer is a heterodimer in which the second polypeptide is selected from VEGF, VEGF-B, VEGF-C, PlGF and PDGF.
Priority Claims (4)
Number |
Date |
Country |
Kind |
PO1825 |
Aug 1996 |
AU |
|
PO3554 |
Nov 1996 |
AU |
|
PO4954 |
Feb 1997 |
AU |
|
PO7435 |
Jun 1997 |
AU |
|
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of the filing dates of the following copending U.S. Provisional Applications: Ser. No. 60/023,751, filed Aug. 23, 1996; Ser. No. 60/031,097, filed Nov. 14, 1996; Ser. No. 60/038,814, filed Feb. 10, 1997; and Ser. No. 60/051,426, filed Jul. 1, 1997.
Foreign Referenced Citations (8)
Number |
Date |
Country |
WO 9524473 |
Sep 1995 |
WO |
WO 9626736 |
Sep 1996 |
WO |
WO 9627007 |
Sep 1996 |
WO |
WO 9639421 |
Dec 1996 |
WO |
WO 9712972 |
Apr 1997 |
WO |
WO 9802543 |
Jan 1998 |
WO |
WO 9807832 |
Feb 1998 |
WO |
WO 9824811 |
Jun 1998 |
WO |
Non-Patent Literature Citations (3)
Entry |
Tischer et al, Biochem. and Biophys. Rsch. Comm. 165(3) :1198-1206 (1989). |
Orlandini et al, Proc. Natl. Acad. Sci. USA 93:11675-11680 (1996). |
Hillier et al, GenBank Accession No. H24828 (1995). |
Provisional Applications (4)
|
Number |
Date |
Country |
|
60/023751 |
Aug 1996 |
US |
|
60/031097 |
Nov 1996 |
US |
|
60/038814 |
Feb 1997 |
US |
|
60/051426 |
Jul 1997 |
US |